Table 1 Demographic and clinical characteristics of the participants
Parameters | Overall (n = 91) | MS with CI (n = 18) | MS without CI (n = 73) | p value | |
|---|---|---|---|---|---|
Age | 31.60 ± 8.64 | 34.88 ± 9.42 | 30.79 ± 8.31 | 0.72 | |
Age groups |  ≤ 20 | 7 (7.7%) | 0 (0%) | 7 (100%) | 0.39 |
21–30 | 43 (47.3%) | 7 (16.27%) | 36 (83.72%) | ||
31–40 | 28 (30.8%) | 7 (25.00%) | 21 (75.00%) | ||
41–50 | 11 (12.1%) | 3 (27.27%) | 8 (72.72%) | ||
51–60 | 2 (2.2%) | 1 (50.00%) | 1 (50.00%) | ||
Sex (male:female) | 26:65 | 4:14 | 22:51 | 0.50 | |
EDSS | 1.29 ± 1.27 | 1.94 ± 1.48 | 1.13 ± 1.17 | 0.01* | |
Disease duration (months) | 70.67 ± 55.18 | 98.66 ± 55.15 | 63.76 ± 53.32 | 0.01* | |
Diagnostic gap (months) | 5.25 ± 11.23 | 5.55 ± 8.03 | 5.17 ± 11.93 | 0.89 | |
Frequency of relapse | 2.84 ± 2.29 | 3.44 ± 2.72 | 2.69 ± 2.17 | 0.22 | |
BDI-FS score | 4.76 ± 3.95 | 5.33 ± 3.91 | 4.63 ± 3.97 | 0.50 | |
Education | 14.05 ± 2.60 | 14.61 ± 2.27 | 11.77 ± 2.66 |  < 0.01* | |
Education groups |  < 12 | 7 (7.7%) | 6 (85.7%) | 1 (14.3%) |  < 0.01* |
12 | 33 (36.3%) | 9 (27.3%) | 24 (72.7%) | ||
12–16 | 39 (42.9%) | 2 (5.1%) | 37 (94.9%) | ||
 > 16 | 12 (13.2%) | 1 (8.3%) | 11 (91.7%) | ||
Disease-modifying drugs | Dimethyl fumarate | 26 (28.6%) | 3 (11.5%) | 23 (88.5%) | 0.02* |
Rituximab | 9 (9.9%) | 5 (55.6%) | 4 (44.4%) | ||
Interferon beta-1 | 30 (33.0%) | 26 (86.7%) | 4 (13.3%) | ||
Natalizumab | 8 (8.8%) | 8 (100%) | 0 (0%) | ||
Fingolimod | 13 (14.3%) | 7 (53.8%) | 6 (46.2%) | ||
No drug for MS | 5 (5.5%) | 4 (80.0%) | 1 (20.0%) | ||